亞洲 核藥
核藥：用放射性同位素當彈頭，精準照射腫瘤。
7追蹤資產
0已核准
這個賽道在做什麼
放射配體療法（RLT）把放射性同位素接在能辨識腫瘤的小分子或胜肽上，藥物到達腫瘤後在近距離放出輻射殺死癌細胞。Pluvicto 與 Lutathera 的成功，讓大藥廠爭相收購核藥公司。同位素供應、製造與配送網路是這個賽道的關鍵門檻。
階段分布
申請／審查1 1
第三期3 3
第二期1 1
第一／二期1 1
第一期1 1
國家分布
韓國2 2
中國4 4
日本1 1
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lu-177-DGUL (pocubotide) | pocubotide (per Korean press; INN spelling not confirmed on WHO list) | Cellbion Co., Ltd. | South Korea | PSMA | 177Lu-labelled small-molecule PSMA radioligand (beta emitter); theranostic pair with Ga-68-NGUL | Registration — South Korea (MFDS conditional approval filed 2025-12-30; under review) | PSMA-positive mCRPC refractory to standard therapy; Ph3 vs SOC approved; Ph1 combo with pembrolizumab | NCT05547061 | None reported (partnering talks reported, no signed deal) | — | — | — | MFDS approved Phase 3 IND (150 pts, 1:1 vs standard care) in mCRPC; conditional approval decision still pending | 2026-09-29 | 1 2 3 | 2026-09-29 |
| 2 | FC705 ([177Lu]Ludotadipep) | ludotadipep | FutureChem Co., Ltd. | South Korea | PSMA | 177Lu-labelled small-molecule PSMA radioligand (beta emitter) | Phase 3 — South Korea (2026-01) | mCRPC (Ph3 Korea, rPFS by BICR); Ph2a in US | NCT07853209 | NCT04509557 | NCT05579184 | None reported for FC705 (FutureChem's China/Europe deals cover diagnostic FC303 only) | — | — | — | Randomized Phase 3 in mCRPC (started 2026-01-26) registered on ClinicalTrials.gov | 2026-10-01 | 1 2 | 2026-10-01 |
| 3 | HRS-4357 | — | Jiangsu Hengrui Pharmaceuticals | China | PSMA | 177Lu-labelled PSMA-targeted radioligand (beta emitter) | Phase 3 — China (2026-02) | PSMA-positive progressive mCRPC vs switch of ARPI (Ph3, n=370); advanced prostate cancer (Ph1/2) | NCT07311694 | NCT06006104 | None reported | — | — | — | Phase 3 vs novel ARPI in PSMA-positive mCRPC started enrolling | 2026-02-02 | 1 2 3 | 2026-02-04 |
| 4 | 177Lu-NYM032 | — | Norroy Bioscience (Wuxi Nuoyu Pharmaceutical Technology) | China | PSMA | 177Lu-labelled small-molecule PSMA radioligand; theranostic pair with 68Ga-NYM032 (same precursor) | Phase 3 — China (NMPA-cleared; registered 2026-08, not yet recruiting) | Progressive PSMA-positive mCRPC vs best standard of care (Ph3, OS endpoint); mCRPC (Ph1/2) | NCT07795268 | NCT06383052 | None reported | — | — | — | Norroy announced NMPA clearance for pivotal Phase 3 of 177Lu-NYM032 in mCRPC | 2026-09-02 | 1 2 3 4 | 2026-09-03 |
| 5 | 177Lu-LNC1011 | — | Yantai Lannacheng Biotechnology (LNC; Dongcheng Pharmaceutical subsidiary) | China | PSMA | 177Lu-labelled small-molecule PSMA ligand (dansyl-modified PSMA ligand) | Phase 2 — China (Ph1/2; Ph2 enrollment completed 2026-01) | PSMA-positive mCRPC; Ph3 planned 1H 2027; 225Ac-LNC1011 follow-on in Ph1/2 | NCT06250244 (IIT) | NCT06377683 (IIT) | None reported | — | — | — | LNC re-filed Hong Kong IPO application disclosing Ph2 enrollment completed (Jan 2026) and Ph3 planned for 1H 2027 | 2026-06-12 | 1 2 3 | 2026-09-10 |
| 6 | TRC003 | — | C Ray Therapeutics (Chengdu) Co., Ltd. | China | PSMA | 225Ac-labelled PSMA-targeted radiopharmaceutical (alpha emitter) | Phase 1/2 — China (2026-05) | Progressive PSMA-positive mCRPC after ARPI or taxane (randomized 3-dose Ph1/2, n=90) | NCT07567521 | None reported | — | — | — | Randomized Phase 1/2 in PSMA-positive mCRPC started | 2026-05-22 | 1 2 | 2026-05-29 |
| 7 | PD-32766T (225Ac-PD-32766) | — | PeptiDream Inc. | Japan | CA9 (carbonic anhydrase IX) | 225Ac-labelled macrocyclic peptide (alpha emitter); theranostic pair with 64Cu-PD-32766D | Phase 1 — US (2026-07) | Relapsed/refractory CA9-positive clear cell renal cell carcinoma | NCT07688187 | None reported (in-house PeptiDream / PDRadiopharma discovery) | — | — | — | Phase 1a/1b theranostic study (64Cu-PD-32766D imaging + 225Ac-PD-32766T therapy) started in the US | 2026-07-07 | 1 2 | 2026-09-18 |